|
1
|
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey
DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN: Diagnosis and
management of multiple myeloma: A review. JAMA. 327:464–477.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Malard F, Neri P, Bahlis NJ, Terpos E,
Moukalled N, Hungria VTM, Manier S and Mohty M: Multiple myeloma.
Nat Rev Dis Primers. 10(45)2024.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yu B, Jiang T and Liu D: BCMA-targeted
immunotherapy for multiple myeloma. J Hematol Oncol.
13(125)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Devasia AJ, Chari A and Lancman G:
Bispecific antibodies in the treatment of multiple myeloma. Blood
Cancer J. 14(158)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Bladé J, de Larrea CF, Rosiñol L, Cibeira
MT, Jiménez R and Powles R: Soft-tissue plasmacytomas in multiple
myeloma: incidence, mechanisms of extramedullary spread, and
treatment approach. J Clin Oncol. 29:3805–3812. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Varettoni M, Corso A, Pica G,
Mangiacavalli S, Pascutto C and Lazzarino M: Incidence, presenting
features and outcome of extramedullary disease in multiple myeloma:
A longitudinal study on 1003 consecutive patients. Ann Oncol.
21:325–330. 2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
D'Agostino M and Raje N: Anti-BCMA CAR
T-cell therapy in multiple myeloma: Can we do better? Leukemia.
34:21–34. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li C, Zhou K, Hu Y, Zou D, Chen L, Chen B,
Liu J, Zhang X, Ren H, Hu K, et al: Equecabtagene autoleucel in
patients with relapsed or refractory multiple myeloma: The
FUMANBA-1 nonrandomized clinical trial. JAMA Oncol. 10:1681–1688.
2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
García-Ortiz A, Rodríguez-García Y,
Encinas J, Maroto-Martín E, Castellano E, Teixidó J and
Martínez-López J: The role of tumor microenvironment in multiple
myeloma development and progression. Cancers (Basel).
13(217)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao Y, Liu Z, Wang X, Wu H, Zhang J, Yang
J, Zhang F, Liu L, Long J, Lu P and Chen Z: Treatment with
humanized selective CD19CAR-T cells shows efficacy in highly
treated B-ALL patients who have relapsed after receiving
murine-based CD19CAR-T therapies. Clin Cancer Res. 25:5595–5607.
2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai
H, Jiang L, Meng L, Yang Y, Zhou X, et al: A phase 1 study of a
novel fully human BCMA-targeting CAR (CT103A) in patients with
relapsed/refractory multiple myeloma. Blood. 137:2890–2901.
2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lacy MQ and McCurdy AR: Pomalidomide.
Blood. 122:2305–2309. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Works M, Soni N, Hauskins C, Sierra C,
Baturevych A, Jones JC, Curtis W, Carlson P, Johnstone TG, Kugler
D, et al: Anti-B-cell maturation antigen chimeric antigen receptor
T cell function against multiple myeloma is enhanced in the
presence of lenalidomide. Mol Cancer Ther. 18:2246–2257.
2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhao G, Wei R, Feng L, Wu Y, He F, Xiao M
and Cheng Z: Lenalidomide enhances the efficacy of anti-BCMA CAR-T
treatment in relapsed/refractory multiple myeloma: A case report
and revies of the literature. Cancer Immunol Immunother. 71:39–44.
2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yan Y, Tu Y, Cheng Q, Zhang J, Wang E,
Deng Z, Yu Y, Wang L, Liu R, Chu L, et al: BCMA CAR-T therapy
combined with pomalidomide is a safe and effective treatment for
relapsed/refractory multiple myeloma. J Transl Med.
22(1087)2024.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Palumbo A, Avet-Loiseau H, Oliva S,
Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S,
Lahuerta JJ, Facon T, et al: Revised international staging system
for multiple myeloma: A report from international myeloma working
group. J Clin Oncol. 33:2863–2869. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kalff A and Spencer A: The t(4;14)
translocation and FGFR3 overexpression in multiple myeloma:
Prognostic implications and current clinical strategies. Blood
Cancer J. 2(e89)2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Schmidt TM, Fonseca R and Usmani SZ:
Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J.
11(83)2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Dima D, Abdallah AO, Davis JA, Awada H,
Goel U, Rashid A, DeJarnette S, Anwer F, Shune L, Raza S, et al:
Impact of extraosseous extramedullary disease on outcomes of
patients with relapsed-refractory multiple myeloma receiving
standard-of-care chimeric antigen receptor T-cell therapy. Blood
Cancer J. 14(90)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Martin T, Usmani SZ, Berdeja JG, Agha M,
Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, et al:
Ciltacabtagene autoleucel, an Anti-B-cell maturation antigen
chimeric antigen receptor T-Cell therapy, for relapsed/refractory
multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol.
41:1265–1274. 2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Munshi NC, Anderson LD Jr, Shah N, Madduri
D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, et al:
Idecabtagene vicleucel in relapsed and refractory multiple myeloma.
N Engl J Med. 384:705–716. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Rodriguez-Otero P, Ailawadhi S, Arnulf B,
Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R,
et al: Ide-cel or standard regimens in relapsed and refractory
multiple myeloma. N Engl J Med. 388:1002–1014. 2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
San-Miguel J, Dhakal B, Yong K, Spencer A,
Anguille S, Mateos MV, de Larrea CF, Martínez-López J, Moreau P,
Touzeau C, et al: Cilta-cel or standard care in
lenalidomide-refractory multiple myeloma. N Engl J Med.
389:335–347. 2023.PubMed/NCBI View Article : Google Scholar
|
